Transforming growth factor-β: an early predictor of a functional cure in chronic hepatitis B treated with interferon

2021 ◽  
pp. 198657
Author(s):  
Li-Li Wu ◽  
Xiao-Yan Li ◽  
Hong Deng ◽  
Dong-Ying Xie ◽  
Yu-Rong Gu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Growth Factor ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Functional Cure ◽  
Early Predictor

Transforming growth factor β as a possible independent factor in chronic hepatitis B

2021 ◽  
Author(s):  
Ming-hui Li ◽  
Yao Lu ◽  
Fang-fang Sun ◽  
Qi-qi Chen ◽  
Lu Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Growth Factor ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Independent Factor

scholarly journals Transforming Growth Factor -β Level Might Be An Independent Factor Related to Occurrence of Chronic Hepatitis B

2021 ◽  
Author(s):  
Ming-hui Li ◽  
Yao Lu ◽  
Fang-fang Sun ◽  
Qi-qi Chen ◽  
Lu Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Growth Factor ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Alanine Aminotransferase ◽  
Transforming Growth Factor ◽  
Independent Factor ◽  
Alanine Aminotransferase Level ◽  
Ifn Γ ◽  
Tgf Β1

Abstract To investigate association between immune cell-related cytokines and development of chronic hepatitis B (CHB). Patients with chronic hepatitis B virus (HBV) infection in immune tolerance (IT, n=30) and hepatitis B envelope antigen (HBeAg) positive CHB (n=250) were enrolled in the study. HBV virus, serological indicators, and plasma cytokine levels were detected at the time of enrollment. The results showed that there were significant differences in median age of patients (27 vs. 31y), alanine aminotransferase level (ALT, 29.85 vs 234.70 U/L), alanine aminotransferase level (AST, 23.40 vs. 114.90 U/L), HBsAg level (4.79 vs. 3.88 log10 IU/ml), HBeAg (1606.36 vs. 862.47 S/CO) and HBV DNA load (8.17 vs 6.71 log10 IU/ml) between IT and CHB groups (all P<0.01). The median values of Fms-like tyrosine kinase 3 ligand (FLT3-L), interferon-γ (IFN-γ), interleukin- 17A (IL-17A) and transforming growth factor- beta (TGF-β1) in IT group were significantly higher than those in CHB group (FLT3-L: 41.62 vs. 27.47 pg/ml; IFN-γ: 42.48 vs. 33.18 pg/ml; IL-17A: 15.66 vs. 8.90 pg/ml; TGF-β1: 4921.50 vs. 2234 pg/ml. All P<0.01). The median values of IFN-a2, TGF-β3 and IL-10 levels in IT group were significantly lower than those in CHB group (IFN-α2: 15.24 vs. 35.78 pg/ml, P=0.000; TGF-β3: 131.69 vs. 162.61 pg/ml, P=0.025; IL-10: 5.02 vs. 7.9 pg/ml, P=0.012). The multivariate logistic regression analysis indicated that TGF-β 1 (OR=0.999, 95% CI 0.999-1.000, P<0.001) and TGF-β2 levels (OR=1.008, 95%CI 1.004-1.012, P <0.001) were significantly associated with the incidence of CHB. The results suggest that TGF-β level might be an independent factor related to the occurrence of CHB.

scholarly journals Influence of Transforming Growth Factor-β1 Gene Polymorphism at Codon 10 on the Development of Cirrhosis in Chronic Hepatitis B Virus Carriers

2010 ◽  
Vol 25 (4) ◽  
pp. 564 ◽  
Author(s):  
Sang Kyun Yu ◽  
Oh Sang Kwon ◽  
Hyuk Sang Jung ◽  
Kyung Suk Bae ◽  
Kwang An Kwon ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Growth Factor ◽  
Hepatitis B ◽  
Gene Polymorphism ◽  
Chronic Hepatitis B ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Chronic Hepatitis B Virus ◽  
B Virus

Effect of recombinant human transforming growth factor β1 on immune responses in patients with chronic hepatitis B

2008 ◽  
Vol 13 (2) ◽  
pp. 62-68 ◽  
Author(s):  
Shinichi Kakumu ◽  
Yuji Ito ◽  
Masahiro Takayanag ◽  
Kentaro Yoshioka ◽  
Takaji Wakita ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Growth Factor ◽  
Hepatitis B ◽  
Immune Responses ◽  
Chronic Hepatitis B ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1

scholarly journals Cytokines and Chemokines in HBV Infection

2021 ◽  
Vol 8 ◽  
Author(s):  
Shihong Zhong ◽  
Tianling Zhang ◽  
Libo Tang ◽  
Yongyin Li
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Interleukin 10 ◽  
Hbv Infection ◽  
Cytokines And Chemokines ◽  
Immune Exhaustion ◽  
Chronic Hepatitis B Virus

Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

scholarly journals The Difference of Hypoxic Inducible Factor-1α, Vascular Endothelial Growth Factor, and Transforming Growth Factor-β1 Based on Liver Fibrosis Severity in Patients with Chronic Hepatitis B

2021 ◽  
Vol 9 (B) ◽  
pp. 91-95
Author(s):  
Libya Husen ◽  
Gontar Alamsyah Siregar ◽  
Masrul Lubis
Keyword(s):  
Chronic Hepatitis ◽  
Growth Factor ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Transforming Growth Factor ◽  
The Difference ◽  
And Gender ◽  
Endothelial Growth Factor ◽  
Tgf Β1

BACKGROUND: Hepatitis B is a global health problem. The disease damages hepatocytes and creates tissue hypoxic condition. Hypoxia triggers production of several mediators such as hypoxic inducible factor (HIF)-1α, vascular endothelial growth factor (VEGF), and transforming growth factor (TGF)-β1. The mediators act in liver fibrosis and cirrhosis, and hepatocellular carcinoma. AIM: The objective of the study was to determine the difference in serum HIF-1α, VEGF, and TGF-β1 levels based on liver fibrosis severity in patients with chronic hepatitis B. MATERIALS AND METHODS: This cross-sectional study was performed in Haji Adam Malik Hospital Medan, Indonesia, from January to July 2020. Subjects were chronic hepatitis B patients aged 18 years or older. Exclusion criteria were other chronic diseases, malignancies, or pregnancy. Liver fibrosis was determined using shear wave elastography and categorized as follow: F1, F2, F3, and F4. Serum HIF-1α, VEGF, and TGF-β1 levels were measured using enzyme-linked immunosorbent assay. Specimens were obtained from venous blood. RESULTS: A total of 63 patients were enrolled in this study with mean age of 40.3 (SD 11.69) years. Subjects were dominated by males (58.7%). There were no differences in serum HIF-1α, VEGF, and TGF-β1 levels based on liver fibrosis grading and also based on hepatitis B envelope antigen (HBeAg) status and gender. Associations between liver fibrosis grading, HBeAg, and gender were absent. There was a positive correlation between liver fibrosis severity and age (r = 0.311, p = 0.013). CONCLUSION: Serum HIF-1α, VEGF, and TGF-β1 levels were not different among chronic hepatitis B patients based on liver fibrosis severity.

scholarly journals Lack of Association Between Transforming Growth Factor Beta 1-509C/T and +915G/C Polymorphisms and Chronic Hepatitis B in Iranian Patients

2014 ◽  
Vol 14 (3) ◽  
Author(s):  
Armin Hosseini Razavi ◽  
Pedram Azimzadeh ◽  
Seyed Reza Mohebbi ◽  
Seyed Masoud Hosseini ◽  
Sara Romani ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Growth Factor ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Growth Factor Beta ◽  
Iranian Patients
Sign in / Sign up

Export Citation Format

Share Document